Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about EYENOVIA, INC.
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
MT
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug Mydcombi™ to Eyenovi..
CI
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
PU
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic..
CI
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evalu..
PU
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30,..
CI
08/11Eyenovia Reports Second Quarter 2021 Financial Results
GL
08/04Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
GL
07/19EYENOVIA : to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
BU
07/07Eyenovia to Participate in Two Upcoming Investor Conferences
GL
06/16Declaration of Voting Results by Eyenovia, Inc
CI
06/15EYENOVIA : highlights Recent Progress in Three Phase 3 Programs, NDA Review Prog..
PU
06/15Eyenovia, Inc. Provides Corporate Update on Pipeline with Recent and Upcoming..
CI
06/15Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Pro..
GL
06/10Stuart M. Grant Provides Information to shareholders of Eyenovia
CI
05/25EYENOVIA : Reports Positive Topline Results From Phase 3 Study of MicroLine to T..
MT
05/25Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical St..
GL
05/25EYENOVIA : Announces Positive Topline Results from VISION-1 Phase 3 Clinical Stu..
PU
05/25Eyenovia, Inc. Announces Positive Topline Data from Its Phase 3 Vision-1 Stud..
CI
05/14EYENOVIA : Completed patient enrollment in Phase 3 VISION-1 study evaluating Mic..
PU
05/12Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/12Eyenovia Reports First Quarter 2021 Financial Results
GL
05/12EYENOVIA : Announces New $25 Million Credit Facility with Silicon Valley Bank (F..
PU
05/10Eyenovia, Inc. Enters into Loan and Security Agreement
CI
05/10Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
GL
05/05Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12
GL
04/20INSIDER TRENDS : Eyenovia Insider 90-Day Buying Trend Prolonged with Purchase
MT
04/01EYENOVIA : HC Wainwright Adjusts Price Target on Eyenovia to $8 From $6, Maintai..
MT
04/01EYENOVIA : Announces Appointment of Renowned Ophthalmologist and Scientific Lead..
BU
04/01Eyenovia Announces Appointment of Julia Haller to Its Board of Directors
CI
03/25EYENOVIA : Pares Q4 Loss, Posts Revenue
MT
03/25Eyenovia, Inc. Reports Earnings Results for the Fourth Quarter Ended December..
CI
03/25Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
GL
03/24EYENOVIA : and EVERSANA Announce Partnership to Support the Potential Launch and..
AQ
03/23EYENOVIA : Teams Up With Eversana to Commercialize MydCombi in US
MT
03/23EYENOVIA : and EVERSANA Announce Partnership to Support the Potential Launch and..
BU
03/23Eyenovia, Inc. and Eversana Announce Partnership to Support the Potential Lau..
CI
03/18EYENOVIA : Announces Publication of MIST Pivotal Studies Demonstrating the Effic..
AQ
03/18EYENOVIA : to Report Fourth Quarter and Full Year 2020 Results on Thursday, Marc..
AQ
03/17EYENOVIA : Announces Publication of MIST Pivotal Studies Demonstrating the Effic..
BU
03/17Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Effi..
CI
03/10EYENOVIA : to Participate in the 33rd Annual Roth Conference
AQ
03/02EYENOVIA : Reports MydCombi New Drug Application Acceptance From US FDA
MT
03/02Eyenovia, Inc. Announces Fda Acceptance of the Mydcombi NDA
CI
03/02EYENOVIA : Announces FDA Acceptance of the MydCombi NDA
BU
03/01EYENOVIA : Northland Starts Eyenovia at Outperform With $10 Price Target
MT
02/16EYENOVIA : to Host Key Opinion Leader Webinar on Presbyopia
AQ
02/03Eyenovia, Inc. Appoints Michael M. Rowe to Chief Operating Officer
CI
01/27EYENOVIA : to Present at the Ophthalmology Innovation Summit Presbyopia Innovati..
AQ
01/26EYENOVIA : to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia In..
BU
01/06EYENOVIA : to Participate in Presbyopia Panel Discussion at the LifeSci Partners..
AQ
2020EYENOVIA : Submits New Drug Application for Pupil Dilation Agent
MT
2020EYENOVIA : Submits New Drug Application to FDA for Pharmacologic Mydriasis with ..
BU
2020Eyenovia, Inc. Submits New Drug Application to FDA for Pharmacologic Mydriasi..
CI
2020EYENOVIA : Enrolls First Set of Patients in Study of Drug Candidate to Improve N..
MT
2020EYENOVIA : Announces First Patients Enrolled in Phase 3 Study of MicroLine for P..
BU
2020Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for ..
CI
2020EYENOVIA : FDA Accepts Eyenovia's Investigational New Drug Application for Micro..
MT
2020Eyenovia, Inc. Announces FDA Acceptance of IND for MicroLine for Presbyopia, ..
CI
2020EYENOVIA : Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearin..
BU
2020EYENOVIA : Reports Third Quarter 2020 Financial Results
AQ
2020Eyenovia, Inc. Reports Earnings Results for the Third Quarter Ended September..
CI
2020EYENOVIA : Reports Third Quarter 2020 Financial Results
AQ
2020Eyenovia Reports Third Quarter 2020 Financial Results
GL
2020EYENOVIA : to Report Third Quarter 2020 Results on Tuesday, November 10
AQ
2020Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
GL
2020Certain Common Stock of Eyenovia, Inc. are subject to a Lock-Up Agreement End..
CI
2020Certain Options of Eyenovia, Inc. are subject to a Lock-Up Agreement Ending o..
CI
2020BAUSCH HEALTH : Licenses Eyenovia's Investigational Treatment for The Reduction ..
AQ
2020BAUSCH HEALTH : Eyenovia to Host Investor Call to Discuss Recent Licensing Agree..
AQ
2020Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulti..
GL
2020Eyenovia, Inc. Receives Up to $45 Million in License Payments of Which $10 Mi..
CI
2020EYENOVIA : Bausch Health Licenses Eyenovia's Investigational Treatment For The R..
AQ
2020EYENOVIA : to Present Clinical Study Updates at the American Academy of Optometr..
BU
2020EYENOVIA : to Present at the 22nd Annual H.C. Wainwright Global Investment Confe..
AQ
1  2  3Next
Upcoming event on EYENOVIA, INC.
11/16/21